Bayer Middle East brings Alleye home monitoring programme to…

Bayer buys Vividion for $1.5bn

Bayer bolsters its drug discovery capabilities through the acquisition of Vividion, which it says will benefit from an arm’s length business model. The deal – which could be worth up to $2 billion – strengthens Bayer’s small molecule oncology and immunology targets...